Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 26, 2025
Daily News
August 26, 2025
- ASKA Presses Dalton for Transparency on 30% Stake Plan
August 26, 2025
- Public-Private Council WG on Drug Discovery to Hold First Meeting Sept. 1
August 26, 2025
- Japan Approves 3 New Drugs, Expands Label for Enhertu, Silgard 9 and More
August 26, 2025
- Meiji Revives Penicillin Raw Material Production in Japan after 31 Years, Races to Pass Down Know-How
August 26, 2025
- Nippon Kayaku to Set Up Singapore-Based JV to License Drugs in Asia
August 26, 2025
- Dayvigo, Jardiance Heavily Promoted in July: Intage
August 26, 2025
- Japan Approves Roche Diagnostics Test for HER2 Ultralow Breast Cancer
August 26, 2025
- Daiichi Sankyo’s TROP2 ADC Datroway Approved in China
August 26, 2025
- Austria, Germany Become First EU Markets to Launch Leqembi
August 26, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…